Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion
Dec. 15, 2021, midnight
Ronald A. Siegel
Changquan Calvin Sun
Remove from favorites
Add to favorites
A hydroxypropyl methylcellulose acetate succinate (HPMC-AS) amorphous solid dispersion (ASD) of sorafenib (SOR), prepared through coprecipitation, was utilized for the development of an immediate release tablet with enhanced oral bioavailability. The chosen ASD, featuring 40% drug loading with HPMC-AS (M grade), demonstrated superior physical stability and improved dissolution properties. The selection of the dry granulation process was based on a systematic characterization of powder properties to address the poor flowability of the ASD.
The tablet formulation was designed and evaluated using an efficient and material-sparing approach to optimize compaction conditions for manufacturing ASD tablets with low friability and rapid disintegration. The resulting SOR ASD tablets displayed approximately 50% higher relative bioavailability in dogs compared to the marketed SOR tablet product, Nexavar®.